Evolution of deep brain stimulation: Human electrometer and smart devices supporting the next generation of therapy

Kendall H Lee, Charles D. Blaha, Paul A. Garris, Pedram Mohseni, April E. Horne, Kevin E. Bennet, Filippo Agnesi, Jonathan M. Bledsoe, Deranda B. Lester, Chris Kimble, Hoon Ki Min, Young Bo Kim, Zang Hee Cho

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Deep brain stimulation (DBS) provides therapeutic benefit for several neuropathologies, including Parkinson disease (PD), epilepsy, chronic pain, and depression. Despite well-established clinical efficacy, the mechanism of DBS remains poorly understood. In this review, we begin by summarizing the current understanding of the DBS mechanism. Using this knowledge as a framework, we then explore a specific hypothesis regarding DBS of the subthalamic nucleus (STN) for the treatment of PD. This hypothesis states that therapeutic benefit is provided, at least in part, by activation of surviving nigrostriatal dopaminergic neurons, subsequent striatal dopamine release, and resumption of striatal target cell control by dopamine. While highly controversial, we present preliminary data that are consistent with specific predications testing this hypothesis. We additionally propose that developing new technologies (e.g., human electrometer and closed-loop smart devices) for monitoring dopaminergic neurotransmission during STN DBS will further advance this treatment approach.

Original languageEnglish (US)
Pages (from-to)85-103
Number of pages19
JournalNeuromodulation
Volume12
Issue number2
DOIs
StatePublished - Apr 2009

Fingerprint

Deep Brain Stimulation
Equipment and Supplies
Corpus Striatum
Subthalamic Nucleus
Parkinson Disease
Dopamine
Therapeutics
Dopaminergic Neurons
Synaptic Transmission
Chronic Pain
Epilepsy
Technology

Keywords

  • Deep brain stimulation
  • Parkinson disease
  • Subthalamic nucleus
  • Voltammetry
  • Wireless integrated circuit

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neurology
  • Clinical Neurology

Cite this

Evolution of deep brain stimulation : Human electrometer and smart devices supporting the next generation of therapy. / Lee, Kendall H; Blaha, Charles D.; Garris, Paul A.; Mohseni, Pedram; Horne, April E.; Bennet, Kevin E.; Agnesi, Filippo; Bledsoe, Jonathan M.; Lester, Deranda B.; Kimble, Chris; Min, Hoon Ki; Kim, Young Bo; Cho, Zang Hee.

In: Neuromodulation, Vol. 12, No. 2, 04.2009, p. 85-103.

Research output: Contribution to journalArticle

Lee, KH, Blaha, CD, Garris, PA, Mohseni, P, Horne, AE, Bennet, KE, Agnesi, F, Bledsoe, JM, Lester, DB, Kimble, C, Min, HK, Kim, YB & Cho, ZH 2009, 'Evolution of deep brain stimulation: Human electrometer and smart devices supporting the next generation of therapy', Neuromodulation, vol. 12, no. 2, pp. 85-103. https://doi.org/10.1111/j.1525-1403.2009.00199.x
Lee, Kendall H ; Blaha, Charles D. ; Garris, Paul A. ; Mohseni, Pedram ; Horne, April E. ; Bennet, Kevin E. ; Agnesi, Filippo ; Bledsoe, Jonathan M. ; Lester, Deranda B. ; Kimble, Chris ; Min, Hoon Ki ; Kim, Young Bo ; Cho, Zang Hee. / Evolution of deep brain stimulation : Human electrometer and smart devices supporting the next generation of therapy. In: Neuromodulation. 2009 ; Vol. 12, No. 2. pp. 85-103.
@article{bd7739eebda144a68c76a3ac042d23db,
title = "Evolution of deep brain stimulation: Human electrometer and smart devices supporting the next generation of therapy",
abstract = "Deep brain stimulation (DBS) provides therapeutic benefit for several neuropathologies, including Parkinson disease (PD), epilepsy, chronic pain, and depression. Despite well-established clinical efficacy, the mechanism of DBS remains poorly understood. In this review, we begin by summarizing the current understanding of the DBS mechanism. Using this knowledge as a framework, we then explore a specific hypothesis regarding DBS of the subthalamic nucleus (STN) for the treatment of PD. This hypothesis states that therapeutic benefit is provided, at least in part, by activation of surviving nigrostriatal dopaminergic neurons, subsequent striatal dopamine release, and resumption of striatal target cell control by dopamine. While highly controversial, we present preliminary data that are consistent with specific predications testing this hypothesis. We additionally propose that developing new technologies (e.g., human electrometer and closed-loop smart devices) for monitoring dopaminergic neurotransmission during STN DBS will further advance this treatment approach.",
keywords = "Deep brain stimulation, Parkinson disease, Subthalamic nucleus, Voltammetry, Wireless integrated circuit",
author = "Lee, {Kendall H} and Blaha, {Charles D.} and Garris, {Paul A.} and Pedram Mohseni and Horne, {April E.} and Bennet, {Kevin E.} and Filippo Agnesi and Bledsoe, {Jonathan M.} and Lester, {Deranda B.} and Chris Kimble and Min, {Hoon Ki} and Kim, {Young Bo} and Cho, {Zang Hee}",
year = "2009",
month = "4",
doi = "10.1111/j.1525-1403.2009.00199.x",
language = "English (US)",
volume = "12",
pages = "85--103",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Evolution of deep brain stimulation

T2 - Human electrometer and smart devices supporting the next generation of therapy

AU - Lee, Kendall H

AU - Blaha, Charles D.

AU - Garris, Paul A.

AU - Mohseni, Pedram

AU - Horne, April E.

AU - Bennet, Kevin E.

AU - Agnesi, Filippo

AU - Bledsoe, Jonathan M.

AU - Lester, Deranda B.

AU - Kimble, Chris

AU - Min, Hoon Ki

AU - Kim, Young Bo

AU - Cho, Zang Hee

PY - 2009/4

Y1 - 2009/4

N2 - Deep brain stimulation (DBS) provides therapeutic benefit for several neuropathologies, including Parkinson disease (PD), epilepsy, chronic pain, and depression. Despite well-established clinical efficacy, the mechanism of DBS remains poorly understood. In this review, we begin by summarizing the current understanding of the DBS mechanism. Using this knowledge as a framework, we then explore a specific hypothesis regarding DBS of the subthalamic nucleus (STN) for the treatment of PD. This hypothesis states that therapeutic benefit is provided, at least in part, by activation of surviving nigrostriatal dopaminergic neurons, subsequent striatal dopamine release, and resumption of striatal target cell control by dopamine. While highly controversial, we present preliminary data that are consistent with specific predications testing this hypothesis. We additionally propose that developing new technologies (e.g., human electrometer and closed-loop smart devices) for monitoring dopaminergic neurotransmission during STN DBS will further advance this treatment approach.

AB - Deep brain stimulation (DBS) provides therapeutic benefit for several neuropathologies, including Parkinson disease (PD), epilepsy, chronic pain, and depression. Despite well-established clinical efficacy, the mechanism of DBS remains poorly understood. In this review, we begin by summarizing the current understanding of the DBS mechanism. Using this knowledge as a framework, we then explore a specific hypothesis regarding DBS of the subthalamic nucleus (STN) for the treatment of PD. This hypothesis states that therapeutic benefit is provided, at least in part, by activation of surviving nigrostriatal dopaminergic neurons, subsequent striatal dopamine release, and resumption of striatal target cell control by dopamine. While highly controversial, we present preliminary data that are consistent with specific predications testing this hypothesis. We additionally propose that developing new technologies (e.g., human electrometer and closed-loop smart devices) for monitoring dopaminergic neurotransmission during STN DBS will further advance this treatment approach.

KW - Deep brain stimulation

KW - Parkinson disease

KW - Subthalamic nucleus

KW - Voltammetry

KW - Wireless integrated circuit

UR - http://www.scopus.com/inward/record.url?scp=65349085578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349085578&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1403.2009.00199.x

DO - 10.1111/j.1525-1403.2009.00199.x

M3 - Article

AN - SCOPUS:65349085578

VL - 12

SP - 85

EP - 103

JO - Neuromodulation

JF - Neuromodulation

SN - 1094-7159

IS - 2

ER -